Lion Point Capital, LP Syndax Pharmaceuticals Inc Transaction History
Lion Point Capital, LP
- $37.2 Million
- Q3 2024
A detailed history of Lion Point Capital, LP transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Lion Point Capital, LP holds 46,200 shares of SNDX stock, worth $631,554. This represents 2.39% of its overall portfolio holdings.
Number of Shares
46,200
Previous 65,000
28.92%
Holding current value
$631,554
Previous $1.33 Million
33.36%
% of portfolio
2.39%
Previous 2.85%
Shares
3 transactions
Others Institutions Holding SNDX
# of Institutions
230Shares Held
90MCall Options Held
1.01MPut Options Held
692K-
Black Rock Inc. New York, NY7.91MShares$108 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.84MShares$79.9 Million9.23% of portfolio
-
Wellington Management Group LLP Boston, MA4.99MShares$68.2 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$66.8 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.11MShares$56.1 Million6.25% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $773M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...